Histology
Undifferentiated Carcinoma
CI-CAN-00001624Explore in graph →
46 active trials2 approved drugs5 evidence items
- NCIt
- C3692
Loading cancer entity…
Histology
CI-CAN-00001624Explore in graph →
Clinical trials
162 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | withdrawn | Phase 1 / Phase 2 | 0 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 |
| clinicaltrials |
| NCT05390021 | PET/MRI in Endometrial Cancer | withdrawn | N/A | 0 | Massachusetts General HospitalOTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers(TAM-RT) | withdrawn | Phase 1 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer(FACT2) | withdrawn | Phase 3 | 0 | Mateon TherapeuticsINDUSTRY | 0 | May 1, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Feb 23, 2026source: clinicaltrials